Open AccessDietary Supplement Use During Chemotherapy and Survival Outcomes of Patients With Breast Cancer Enrolled in a Cooperative Group Clinical Trial (SWOG S0221)
Author(s) -
Christine B. Ambrosone,
Gary Zirpoli,
Alan D. Hutson,
William McCann,
Susan E. McCann,
William E. Barlow,
Kara M. Kelly,
Rikki A. Cannioto,
Lara E. SuchestonCampbell,
Dawn L. Hershman,
Joseph M. Unger,
Halle C. F. Moore,
James A. Stewart,
Claudine Isaacs,
Timothy J. Hobday,
Muhammad Salim,
Gabriel N. Hortobágyi,
Julie R. Gralow,
G. Thomas Budd,
Kathy S. Albain
Publication year - 2020
Publication title -
journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.482
H-Index - 548
eISSN - 1527-7755
pISSN - 0732-183X
DOI - 10.1200/jco.19.01203
Subject(s) - medicine , hazard ratio , breast cancer , proportional hazards model , chemotherapy , cancer , oncology , clinical trial , vitamin e , cyclophosphamide , confidence interval , antioxidant , biochemistry , chemistry
Despite reported widespread use of dietary supplements during cancer treatment, few empirical data with regard to their safety or efficacy exist. Because of concerns that some supplements, particularly antioxidants, could reduce the cytotoxicity of chemotherapy, we conducted a prospective study ancillary to a therapeutic trial to evaluate associations between supplement use and breast cancer outcomes.